COVID-19

Bivalent boosters in development for COVID-19

 

The U.S. Food and Drug Administration will meet later this month to consider approval of two bivalent COVID-19 booster vaccines that are reportedly effective against the Omicron variant (B.1.1.529). Both boosters were developed by Moderna and are variations of the company’s original mRNA-1273 vaccine. Read More

Excess mortality during pandemic tops 14 million

 

The World Health Organization estimates that excess mortality during the COVID-19 pandemic (2020-2021) globally was 14.91 million. Excess mortality includes reported COVID deaths (5.42 million) as well as unreported COVID deaths, all-cause mortality where COVID played a role, and excess deaths related to healthcare delivery. This methodology was used to more accurately reflect deaths directly and indirectly related to the pandemic. Read More

Neurological sequelae of COVID-19 infection

 

A number of recent studies have reported on the incidence of acute neurological complications of COVID-19 infection, as well as long-term complications, variously called PASC (post-acute sequelae of COVID-19) or ‘long COVID’. Data were reported at the American Academy of Neurology annual meeting, held April 2-7 in Seattle, Washington. Read More

Worse COVID-19 outcomes due to disability, morbidity

 

The severe COVID-19 outcomes seen in MS patients do not appear attributable to an inherent immune dysfunction or an impaired antiviral response, but rather to MS-related disability and morbidity. That is the conclusion of the Italian MuSC-19 Study Group in its analysis of COVID-19 in MS patients (Sormani et al. Neurol Neuroimmunol Neuroinflamm 2022;9:e1105). Read More